Cancer statistics, 2008
- PMID: 18287387
- DOI: 10.3322/CA.2007.0010
Cancer statistics, 2008
Abstract
Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Incidence and death rates are age-standardized to the 2000 US standard million population. A total of 1,437,180 new cancer cases and 565,650 deaths from cancer are projected to occur in the United States in 2008. Notable trends in cancer incidence and mortality include stabilization of incidence rates for all cancer sites combined in men from 1995 through 2004 and in women from 1999 through 2004 and a continued decrease in the cancer death rate since 1990 in men and since 1991 in women. Overall cancer death rates in 2004 compared with 1990 in men and 1991 in women decreased by 18.4% and 10.5%, respectively, resulting in the avoidance of over a half million deaths from cancer during this time interval. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, education, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends. Although much progress has been made in reducing mortality rates, stabilizing incidence rates, and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years. Further progress can be accelerated by supporting new discoveries and by applying existing cancer control knowledge across all segments of the population.
Similar articles
-
Cancer statistics, 2007.CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43. CA Cancer J Clin. 2007. PMID: 17237035
-
Cancer statistics, 2009.CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27. CA Cancer J Clin. 2009. PMID: 19474385
-
Cancer statistics, 2010.CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. CA Cancer J Clin. 2010. PMID: 20610543
-
Cancer statistics, 2004.CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. doi: 10.3322/canjclin.54.1.8. CA Cancer J Clin. 2004. PMID: 14974761 Review.
-
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99. doi: 10.1093/jnci/djg040. J Natl Cancer Inst. 2003. PMID: 12953083 Review.
Cited by
-
The cGAS-STING pathway and female reproductive system diseases.Front Immunol. 2024 Oct 9;15:1447719. doi: 10.3389/fimmu.2024.1447719. eCollection 2024. Front Immunol. 2024. PMID: 39445027 Free PMC article. Review.
-
MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal Cancer.Front Mol Biosci. 2021 May 7;8:624873. doi: 10.3389/fmolb.2021.624873. eCollection 2021. Front Mol Biosci. 2021. PMID: 34026821 Free PMC article.
-
In vitro anti-proliferative effects of Zuojinwan on eight kinds of human cancer cell lines.Cytotechnology. 2014 Jan;66(1):37-50. doi: 10.1007/s10616-013-9534-x. Epub 2013 Feb 9. Cytotechnology. 2014. PMID: 23397442 Free PMC article.
-
Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response.Oncotarget. 2015 Sep 15;6(27):24550-9. doi: 10.18632/oncotarget.4076. Oncotarget. 2015. PMID: 26093084 Free PMC article.
-
Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.PLoS One. 2013;8(2):e55637. doi: 10.1371/journal.pone.0055637. Epub 2013 Feb 8. PLoS One. 2013. PMID: 23409011 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical